ADVERTISEMENT

OT: Stock and Investment Talk

Great article, who are the top fund managers buying? SCHW tops the list!

@phs73rc77gsm83 - Lots of folks also buying PFE.


SJMZPQWEPJF2BGQRSFLRG6NDPM.png
 
  • Like
Reactions: T2Kplus20
Wouldn’t this be quite the wonder drug if it does even more than treat diabetes and lately weight loss.

It treats addiction? But. But. But no more hookers and blow? 😢
 
  • Haha
Reactions: rutgersguy1
It treats addiction? But. But. But no more hookers and blow? 😢
Well the high can be replaced by the high you feel if you own NVO lol.

Actually, you know what maybe not. If it's affecting dopamine for the bad stuff, I guess it probably affects dopamine for the good things too. So you'll be a very rich dull boring person lol.
 
  • Like
Reactions: mildone
I sold $28 calls on AI thursday which expired worthless. I will try to sell more at a different strike price this week. Don't mind being called out. I will buy the sock in again.
Looking at AI's chart, the volume which it has sold at in 2023 dwarfs it's historical average(only became public late 2020).

And the trend in 2023 is the stock price spikes on high volume, then slips downward as volume abates. This most recent run here in late may was more modest in terms of price appreciation as well as volume relative for 2023, but still very significant relative to it's historical. Point being, we just had a volume spike, and if trend continues I expect volume to mellow, and the price to come down. So I think you may be able to tighten up the call strike price.

Currently $26.50. I'm short this weeks $23.50 puts, probably a decent bet those expire, but I may look to lower that strike going fwd.

For anyone interested in the fundamentals here, market cap of $3b, currently not profitable, and not expected to be as far out as 2025, price to rev's pretty expensive at $11x, with pretty modest rev growth around 15-20%, both in it's short history and the projected's. Unless those projections are way under (or maybe a buyout possibility) I don't see this as a good entry point as an investment.
 
Any opinions on BUD? If it were to drop more into the high 40s low 50s, I think it could be interesting. Controversy might knock it down for a bit but often these things are temporary.
Seems somewhat reminiscent of many fans writing off the NFL because of those kneeling during the anthem. As we know, that has completely blown over.

Not sure if the recent controversies are baked into current projections, but OK rev growth looking fwd, but excellent EPS growth. Current P/E of 16x, EPS of $3.20. EPS of $5 expected in 2026. P/E prior to Covid lows over 20x.

Throw a 20x on those 2026 earnings and you have a $100 stock.

I agree wait to see where it settles. It bounced after the initial controversy dip, but has since fell below that initial low. So I wouldn't bet this is the near term low.

Might be support in the mid $50's? 2022 lows in the mid $40's. Covid lows around $40.
 
Last edited:
  • Like
Reactions: rutgersguy1
SCHW in the low 60’s would be enticing.
Currently in the low $50's? Are we waiting for an upward trend before buying?

Looking back to 2018, and pre covid levels, low 50's could be a support level.
 
STNE down around $12.80, off it's highs over $14.

I'm short the $12.50 puts. See if my thesis holds that past resistance at around $12 becomes support.
 
Seems somewhat reminiscent of many fans writing off the NFL because of those kneeling during the anthem. As we know, that has completely blown over.

Not sure if the recent controversies are baked into current projections, but OK rev growth looking fwd, but excellent EPS growth. Current P/E of 16x, EPS of $3.20. EPS of $5 expected in 2026. P/E prior to Covid lows over 20x.

Throw a 20x on those 2026 earnings and you have a $100 stock.

I agree wait to see where it settles. It bounced after the initial controversy dip, but has since fell below that initial low. So I wouldn't bet this is the near term low.

Might be support in the mid $50's? 2022 lows in the mid $40's. Covid lows around $40.
It's lingering around the 200DMA now and it could hold there for a bit but if not that's where I'm thinking a more significant drop might come.

The TGT controversy some years back was what was on my mind and that blew over like they usually do.
 
I own PLTR. On a great rip this month, since it too said the magic words.

Think it might be a similar story to AI, with a high volume/stock price spike, followed by a tail off, so I sold next week's $12 calls for 4ish% premium.

If it gets called away, I'm good for a 45ish% win.(plus some premiums along the way, but not a lot).
 
It's lingering around the 200DMA now and it could hold there for a bit but if not that's where I'm thinking a more significant drop might come.

The TGT controversy some years back was what was on my mind and that blew over like they usually do.
A potential difference between BUD and the NFL is there are alternatives to the former.

So an old timey bud drinker may switch beers rather then associate with a trans girl every time he drinks a beer.

And I don't see a ton of Devan(is that her name?) fans becoming bud lite drinkers.
 
A potential difference between BUD and the NFL is there are alternatives to the former.

So an old timey bud drinker may switch beers rather then associate with a trans girl every time he drinks a beer.

And I don't see a ton of Devan(is that her name?) fans becoming bud lite drinkers.
There were alternatives to TGT but these things eventually run their course.
 
SNOW seems to be primed for a run. Technicals look very good. Next week is earnings. I am looking for it to get to the ~$200-205 level in the next few weeks. Option prices are elevated so good time to sell out of the money calls as well.
In 40 SNOW @ 173 this morning.
 
Other than my normal buying schedule, I am tracking CURE very closely. Will buy more if it dips below $90. This will increase my CB a bit (which is around $86-87), but I'm super bullish on HC for the next few years.
 
We should find out in the next few hours whether that trade is going our way.
I usually don’t buy ahead of earnings but we’ll see. Maybe they’ll announce some AI developments or that they bought Neeva, because investing in cloud hyper scaling is so 2021.
 
I usually don’t buy ahead of earnings but we’ll see. Maybe they’ll announce some AI developments or that they bought Neeva, because investing in cloud hyper scaling is so 2021.
Announcing something regarding AI is a lock.
 
We’ve held PFE for a long time. Lots of potentially great drugs being developed in the industry.
One of the first stocks I ever bought 20 plus years ago through a DRIP. Honestly, I think it’s been a dog for that time period. I still own it through that but I’m quite eh about it for the most part.

Had a lot of trouble replacing Lipitor and got so big it took a ton to move the needle in terms of growth.
 
We’ve held PFE for a long time. Lots of potentially great drugs being developed in the industry.
PFE's earnings look to be down pretty significantly yoy now that Covid vaccine's are behind us.

Still it did beat by 25% in the first quarter, and even with current projected EPS it's at about 12x 2023 earnings. And healthy beats are pretty much the norm for PFE.

Current P/E of 7x ttm. Current div of 4%.
 
Currently in the low $50's? Are we waiting for an upward trend before buying?

Looking back to 2018, and pre covid levels, low 50's could be a support level.
Oops, Fat finger. My eye sight is going. I thought SCHD was the one in question. SCHD (etf) in the low 60’s is the one I’m really interested in. I’ll be watching closely at those levels and be ready to pounce.
 
  • Like
Reactions: RUinPinehurst
Oops, Fat finger. My eye sight is going. I thought SCHD was the one in question. SCHD (etf) in the low 60’s is the one I’m really interested in. I’ll be watching closely at those levels and be ready to pounce.
Glad you clarified because I was wondering too like @RU-05. I have noticed dividends stocks have been taken a little more of hit lately.

I’ve always that they should have with rates rising but really haven’t seen it.
 
One of the first stocks I ever bought 20 plus years ago through a DRIP. Honestly, I think it’s been a dog for that time period. I still own it through that but I’m quite eh about it for the most part.

Had a lot of trouble replacing Lipitor and got so big it took a ton to move the needle in terms of growth.
PFE was a mid $40's stock way back in 1999. Topped out at around that level in 2000, then fell into the teens in 2008. Pressed up against that mid 40's level again in 2018 before falling off.

Broke through post Covid, but couldn't hold. Now is it still in a support level?

Current P/E is right about where it was at the lows in 2008-2009.
 
Even with the rev beat, and the stock sell off after hours, SNOW's price to rev's at 22x.
 
PFE's earnings look to be down pretty significantly yoy now that Covid vaccine's are behind us.

Still it did beat by 25% in the first quarter, and even with current projected EPS it's at about 12x 2023 earnings. And healthy beats are pretty much the norm for PFE.

Current P/E of 7x ttm. Current div of 4%.
Great thing about all that COVID cash was having the resources for M&A and increased internal R&D spending. That's how a pharma company overcomes a significant patent cliff (which happens for Pfizer in 2026-2027). I think they are well positioned to mitigate this risk.
 
Last edited:
  • Like
Reactions: phs73rc77gsm83
Nvidia is a machine. I wish I owned some
BOOM!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

🚀🚀🚀🚀🚀🚀🚀

One of my biggest holdings (#4 behind MSFT, AAPL, and GOOGL).
 
  • Like
Reactions: Postman_1
PFE was a mid $40's stock way back in 1999. Topped out at around that level in 2000, then fell into the teens in 2008. Pressed up against that mid 40's level again in 2018 before falling off.

Broke through post Covid, but couldn't hold. Now is it still in a support level?

Current P/E is right about where it was at the lows in 2008-2009.
What's in the DRIP I've held all along but anything outside of that I just trade. It's not a stock I think much of in the pharma space, it's average at best. Back then biotechs like Genentech, Celgene, Amgen would've been better and then a tried and true name like JNJ as well which I have also held for long time.

PFE IMO has mostly been mismanaged and became too big with acquisitions to obtain drugs. Spent a lot on R&D during those 20 plus years but not sure they ever came out with ton on their own and certainly not much to move the needle for a company that size.
 
  • Like
Reactions: RU-05
ADVERTISEMENT

Latest posts

ADVERTISEMENT